NEW YORK, June 10 - First Genetic Trust, of Chicago, and Galileo Genomics are collaborating to provide pharmacogenomics services to pharma and biotech, the companies said today.
"The US FDA is on the threshold of creating a regulatory framework to allow pharmacogenomics to better treat individuals through improved drug development. The combined assets of First Genetic Trust and Galileo will allow us to assist the pharmaceutical industry to develop safer and more effective drugs," said Dr. John Hooper, CEO of Galileo Genomics, said in a statement.
In the collaboration, Galileo, of
First Genetic Trust will contribute its enTrust genetic banking platform, as well as the channels it has established for recruiting patients in the US for large-scale studies to validate discoveries made in the founder populations. The company, based in